Over the past few decades, long acting injectable (LAI) depots of polylactide-co-glycolide
(PLGA) or polylactic acid (PLA) based microspheres have been developed for controlled …

Poly (lactic-co-glycolic acid)(PLGA) microspheres are a sustained-release drug delivery
system with several successful commercial products used for the treatment of a variety of …

Poly (lactic-co-glycolic acid)(PLGA) has been used in many long-acting drug formulations
which have been approved by the US Food and Drug Administration (FDA). However …

Poly (lactic-co-glycolic acid)(PLGA) has garnered increasing attention as a candidate drug
delivery polymer owing to its favorable properties, including its excellent biocompatibility …

Poly (lactic-co-glycolic acid)(PLGA) is one of the preferred polymeric inactive ingredients for
long-acting parenteral drug products that are constituted of complex formulations. Despite …

The increasing focus on patient centricity in the pharmaceutical industry over the past
decade and the changing healthcare landscape, driven by factors such as increased access …

Biopolymeric microparticles have been widely used for long-term release formulations of
short half-life chemicals or synthetic peptides. Characterization of the drug release from …

Abstract Adopting the Quality by Design (QbD) approach in the drug development process
has transformed from “nice-to-do” into a crucial and required part of the development …

Long-acting injectable (LAI) formulations can provide several advantages over the more
traditional oral formulation as drug product opportunities. LAI formulations can achieve …

The objective of the present study was to investigate the effect of molecular weight
differences of poly (lactic-co-glycolic acid)(PLGA) on the in vitro release profile of …